Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. (Record no. 25961795)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02230 a2200673 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517092716.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201712s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1569-8041 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1093/annonc/mdw174 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Chatterjee, M |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20171227 |
| 245 00 - TITLE STATEMENT | |
| Title | Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Annals of oncology : official journal of the European Society for Medical Oncology |
| Date of publication, distribution, etc. | 07 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1291-8 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | B7-H1 Antigen |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carcinoma, Non-Small-Cell Lung |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease-Free Survival |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Dose-Response Relationship, Drug |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug-Related Side Effects and Adverse Reactions |
| General subdivision | pathology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | ErbB Receptors |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gene Expression Regulation, Neoplastic |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasm Staging |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Prognosis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Turner, D C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Felip, E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lena, H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cappuzzo, F |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Horn, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Garon, E B |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hui, R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Arkenau, H-T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gubens, M A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hellmann, M D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dong, D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Li, C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mayawala, K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Freshwater, T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ahamadi, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stone, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lubiniecki, G M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zhang, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Im, E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | De Alwis, D P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kondic, A G |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fløtten, Ø |
| 773 0# - HOST ITEM ENTRY | |
| Title | Annals of oncology : official journal of the European Society for Medical Oncology |
| Related parts | vol. 27 |
| -- | no. 7 |
| -- | p. 1291-8 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1093/annonc/mdw174">https://doi.org/10.1093/annonc/mdw174</a> |
| Public note | Available from publisher's website |
No items available.